Compare KODK & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KODK | HELP |
|---|---|---|
| Founded | 1880 | 2019 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 982.9M | 862.2M |
| IPO Year | 1994 | 2020 |
| Metric | KODK | HELP |
|---|---|---|
| Price | $9.37 | $10.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $41.40 |
| AVG Volume (30 Days) | 680.2K | ★ 1.3M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,114,000,000.00 | N/A |
| Revenue This Year | $10.63 | N/A |
| Revenue Next Year | $6.60 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.78 | $3.76 |
| 52 Week High | $14.87 | $15.15 |
| Indicator | KODK | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 50.29 | 43.27 |
| Support Level | $9.20 | $9.97 |
| Resistance Level | $10.19 | $14.75 |
| Average True Range (ATR) | 0.30 | 0.93 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 57.25 | 21.68 |
Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.